News & Announcements
-
Director/PDMR Shareholding
/**/ RNS Number : 3367X IQ-AI Limited 04 January 2022 4 January 2022 IQ-AI Ltd (“IQ-AI” or the “Company”) Director/PDMR Shareholding IQ-AI announces that Michael Schmainda, Director of IQAI and CEO of Imaging Biometrics, has been granted an option to subscribe for 5,969,792 ordinary shares of 1p each in the Company (“Ordinary
-
IQ-AI Prepares for Phase 1 Clinical Trial Launch
/**/ RNS Number : 0182W IQ-AI Limited 17 December 2021 17 December 2021 IQ-AI LIMITED (“IQ-AI” or the “Company”) IQ-AI Prepares for Phase I Clinical Trial Launch IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), IQ-AI has been working with the clinical team at the Medical College of Wisconsin (MCW) to qualify a new supplier for
-
Director’s Interest
/**/ RNS Number : 4300V IQ-AI Limited 13 December 2021 13 December 2021 IQ-AI Ltd (“IQ-AI” or the “Company”) Director’s Interest IQ-AI has been advised that Trevor Brown, Chief Executive of the Company, no longer has an interest in Free Association Books Limited. Accordingly, Trevor Brown’s interest in the Company is now
-
MD ANDERSON ADOPTS IB CLINIC
/**/ RNS Number : 0487R IQ-AI Limited 02 November 2021 FOR IMMEDIATE RELEASE MD ANDERSON ADOPTS IB CLINIC FOR BRAIN TUMOR ANALYSIS Installation Includes IB Neuro™ and IB DCE™ Software Purchase also Includes IB Clinic – Mac Edition Milwaukee – 2 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer and manufacturer
-
Letter to Shareholders
/**/ RNS Number : 6279Q IQ-AI Limited 28 October 2021 28 October 2021 IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI LIMITED ISSUES SHAREHOLDER LETTER Company Enjoys Most Successful Year on Record Marked Increase in Revenue and Growing Technology Portfolio Sponsorship of a Phase I Clinical Trial Milwaukee – 28 October 2021: IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), a